title: What can HIV vaccine trials teach us about future HIV vaccine dissemination?
abstract: This investigation explored commonalities and differences in barriers and motivators to HIV vaccine trial participation and acceptability of future U.S. Food and Drug Administration (FDA)-approved HIV vaccines in order to identify implications of clinical trials for future HIV vaccine dissemination. Fifteen focus groups were conducted with 157 predominately ethnic minority and low income participants recruited using venue-based sampling in Los Angeles. Data were analyzed using narrative thematic analysis. Barriers and motivators in common across willingness to participate (WTP) in HIV vaccine trials and future HIV vaccine acceptability (e.g., concerns about vaccine-induced infection, false-positives, side effects, efficacy, mistrust and stigma) suggest clinical trials present significant opportunities to develop and evaluate empirically based interventions to support future HIV vaccine dissemination. Barriers specific to HIV vaccine acceptability (e.g., concerns about duration of protection, cross-clade protection, cost and access) also indicate the need for formative research focused specifically on future dissemination. Protection motivation, common to WTP and acceptability, highlights the need to provide and evaluate prevention counseling and education in clinical trials, which may form the basis of evidence-informed preventive interventions to be launched in tandem with dissemination of partial efficacy HIV vaccines.
authors.affiliation: University of Toronto, Centre for Applied Social Research, Faculty of Social Work, 246 Bloor Street West, Toronto, Ontario, Canada M5S 1A1. p.newman@utoronto.ca
authors.forename: Peter A
authors.initials: PA
authors.lastname: Newman
authors.forename: Naihua
authors.initials: N
authors.lastname: Duan
authors.forename: Lisa
authors.initials: L
authors.lastname: Kakinami
authors.forename: Kathleen
authors.initials: K
authors.lastname: Roberts
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D017144:Focus Groups; D006801:Humans; D015141:Los Angeles; D008297:Male; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data*; D014611:Vaccination / Q000523:psychology*
chemical_list: D016915:AIDS Vaccines